Clinical Trials Logo

Clinical Trial Summary

The septate uterus is the most common structural uterine anomaly. It results from failure of the partition between the two fused Müllerian ducts to resorb;it is associated with the highest incidence of reproductive failure and with first- and second-trimester pregnancy loss and infertility.

Hysteroscopic division of the uterine septum is performed using microscissors, electrosurgery, or laser. Several studies shown significant improvement in pregnancy outcome after hysteroscopic metroplasty.

Purpose of this study is to verify the effectiveness of 5 ml, instead of 10 ml, of autocross-linked hyaluronic acid gel in the prevention of the formation of intrauterine adhesions, through second look office hysteroscopy after three months.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT02404454
Study type Interventional
Source University of Cagliari
Contact
Status Not yet recruiting
Phase N/A
Start date June 2016
Completion date March 2017

See also
  Status Clinical Trial Phase
Completed NCT02313415 - Treatment of Infertility by Collagen Scaffold Loaded With Umbilical Cord Derived Mesenchyma Stem Cells N/A
Not yet recruiting NCT02132104 - Efficiency of Amnion Graft to Prevent Intrauterine Adhesions After Hysteroscopic Surgery N/A
Completed NCT02744807 - Role of Chronic Endometritis in Postoperative Recurrence of Severe Intrauterine Adhesions N/A
Terminated NCT01632202 - Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy Phase 4
Recruiting NCT03731689 - Treatment of Intrauterine Adhesions and Its Distribution of Genital Tract Flora N/A
Recruiting NCT02496052 - The Efficacy and Safety of the Dried Biological Amnion Graft in Patients With Intrauterine Adhesions N/A
Recruiting NCT02204358 - Treatment of Infertility by Collagen Scaffold Loaded With Autologous Bone Marrow Stem Cells Phase 4